Journey Medical (NASDAQ:DERM) Posts Quarterly Earnings Results, Beats Estimates By $0.30 EPS

Journey Medical (NASDAQ:DERM) announced its earnings results on Wednesday. The company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.30, Zacks reports. The company had revenue of $14.30 million during the quarter, compared to the consensus estimate of $14.21 million. Journey Medical had a negative return on equity of 132.10% and a negative net margin of 31.74%.

Journey Medical Stock Up 0.9 %

Shares of NASDAQ:DERM traded up $0.06 during trading on Friday, hitting $5.98. The stock had a trading volume of 13,226 shares, compared to its average volume of 86,190. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 1.81. Journey Medical has a 12 month low of $3.20 and a 12 month high of $6.89. The company has a market capitalization of $124.84 million, a PE ratio of -6.36 and a beta of 0.97. The firm’s fifty day moving average is $5.05 and its 200 day moving average is $5.16.

Wall Street Analyst Weigh In

Separately, Alliance Global Partners reissued a “buy” rating on shares of Journey Medical in a research report on Thursday. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $9.67.

Insider Buying and Selling

In other news, CEO Claude Maraoui sold 18,147 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $5.13, for a total transaction of $93,094.11. Following the sale, the chief executive officer now owns 2,092,874 shares in the company, valued at approximately $10,736,443.62. The trade was a 0.86 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 105,831 shares of company stock valued at $536,622 over the last ninety days. Company insiders own 13.16% of the company’s stock.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.